4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Code in Amended SEC Filing

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct a transaction code error related to a common stock purchase.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amended Form 4 with the SEC on July 31, 2024.
• The amendment corrects an error in the original filing from April 25, 2024, which incorrectly stated the transaction code as 'A' instead of 'P'.
• The corrected filing reflects a purchase of 15,000 shares of common stock on April 19, 2024, at a price of $0.5199 per share.
• Following the transaction, Lebovits directly owns 858,565 shares and may be deemed the beneficial owner of 2,000,847 indirectly held shares.
• The indirectly held shares include 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a minor error, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure related to insider trading activity and is required by the SEC to ensure transparency in the market.

Key Dates

Keywords

SEC Filing, Form 4, Amendment, Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Common Stock, Transaction Code, Beneficial Ownership